# A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

> **NCT07205159** · PHASE1 · RECRUITING · sponsor: **Forte Biosciences, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** FB102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07205159
- **Lead sponsor:** Forte Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2027-03-10
- **Final completion:** 2027-03-10
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205159, "A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07205159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*